Abzena, an end-to-end CDMO for biologics and bioconjugates, has launched AbZelect and AbZelectPRO cell line development (CLD) platforms to accelerate cell lie production for manufacturing antibodies and recombinant proteins.
Sphere Fluidics, a UK company that has developed and is commercializing single cell analysis systems underpinned by its picodroplet technology, has just closed a US$40m investment round.
Samsung Biologics is providing contract development services for GI Innovation’s pipeline, with the first among five molecules to initiate development immediately, says company representative.
Abzena and Lipum enter agreement for the development of biologics for juvenile idiopathic arthritis, using the former’s proprietary cell line and GMP resources.
The global cell line development market grows steadily with a predicted revenue of $7.5bn by 2024, each component of the market to see CAGR between 10-15%.
The WHO establishes a multi-disciplinary committee to advise on the ethical and scientific challenges of human genome editing, as the technology’s capability and utilization grows in the industry.
ICT is developing upon CAR-T cell technology to enable T-cells to persist against cancer’s attempt to program death into a patient’s defensive T-cells, which could potentially treat solid tumors.
A study published by graduate students at MIT showed that a synthetic mRNA-based ‘programming language’ can control protein expression in gene therapy.
Dyadic’s CHO-alternative, the C1 production platform, could reduce time and cost at almost every stage of the cell development and biomanufacturing process, says CEO.
Selexis and Xencor have entered into a strategic agreement which strengthens an existing relationship for multi-specific antibody cell line development
Catalent has increased its stake in Redwood Biosciences telling us it is committed to the development of antibody-drug conjugates (ADCs) and the SMARTag technology platform.
As Cobra wins a cell line development contract with Recopharma, the firm says its cost-effective gene expression technology has been its biggest growth area.
Cobra Biologics claims a new micro bioreactor technology it has adopted can cut three months off cell line development timelines and facilitate faster production scale-up.
Catalent Pharma Solutions and German expression system developer Cevec Pharmaceuticals have partnered to create a cell development service that, they claim, will help drugmakers generate stable lines faster.
Californian biotech tool manufacturer Life Technologies has teamed with German contract research organisation (CRO) ProBiogen to release a range of royalty-free Gibco Freedom Cell Line Development Kits.
